| Background Colorectal cancer was the most common clinical endanger people's lives and health of one of the malignant tumor,In 2006 the Ministry of Health statistics show that mortality rate of colorectal cancer has been ranked No. 5 in china,Although the conduct of early curative surgery, the recurrence rate of colorectal cancer mortality rate is still quite high,Surgical treatment of colorectal cancer despite years of efforts, improve the treatment effect was not obvious for colorectal cancer after chemotherapy has been less than satisfactory , In recent years, new chemotherapy drugs and the emergence of chemotherapy, and for the effective micro-metastasis chemotherapy has done a lot of work, in order to prolong the survival period of patients with colorectal cancer and improving quality of life and make a new contribution , Currently, the new adjuvant chemotherapy as a preoperative chemotherapy can reduce the activity of tumor cells, or even the eradication of metastatic lesions and blood scattered cancer cells, so that recurrence and metastasis to minimize the possibility to improve the prognosis, The research group found in previous studies: neo-adjuvant chemotherapy significantly promoted the apoptosis of colon cancer, this study was designed to expand the detection of colorectal cancer Neoadjuvant chemotherapy before and after tumor necrosis and apoptosis rates of change and clinical prognosis , hospitalization time and costs of clinical indicators, etc. In depth study of neoadjuvant chemotherapy patients receiving chemotherapy sensitivity, so as to pre-and postoperative adjuvant chemotherapy for the choice of the program to adjust to provide a new standard for the integrated treatment of colorectal cancer and clinical practice to provide a new direction and approach.Objective According to FOLFOX4 (oxaliplatin +5- FU + CF) neo-adjuvant chemotherapy in colorectal cancer cell apoptosis in the changes in patients with colorectal cancer to determine the degree of sensitivity of the program and related clinical indicators。Methods 126 cases of colorectal cancer patients divided into well differentiated, poorly differentiated (including undifferentiated),moderately differentiated, three groups, according to the same patients before chemotherapy and after tumor cell necrosis, apoptosis (AI) and related changes in clinical indicators, and explore new the clinical significance of adjuvant chemotherapy.Results Adoption of the colorectal cancer patients receiving neoadjuvant chemotherapy before and after the organizational changes in immunohistochemical staining, we found that patients receiving neo-adjuvant chemotherapy in tumor tissue necrosis significantly increased (P <0.05),accept the new adjuvant chemotherapy in the length of stay, hospital charges than those without the recipient, and a better prognosis (P <0.05) , poorly differentiated, moderately differentiated, well-differentiated group of patients with colorectal cancer in the neo-adjuvant chemotherapy prior to AI were 2.43±1.78%, 3.61±1.15%, 3.51±0.31%, while the AI after chemotherapy were 3.50±0.07%, 5.13±0.24%, 3.50±0.07%, poorly differentiated, the differentiation group after chemotherapy compared with chemotherapy before AI there was a significant difference.Conclusion 1)Neo-adjuvant chemotherapy significantly promoted necrosis and apoptosis in colon cancer cells。2)After neoadjuvant chemotherapy apoptotic index was significantly higher than before chemotherapy, suggesting that neo-adjuvant chemotherapy on tumor cells a significant therapeutic effect。3)Acceptance of neo-adjuvant chemotherapy in patients with length of stay, hospital charges, and prognosis is significantly better than that of patients is not... |
PDF Full Text Request